
Issued: June 2012.
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen by National Institute for Health and Clinical Excellence. Published by National Institute for Health and Clinical Excellence in 2012. Publication and catalogue information, links to buy online and reader comments.